News and breakthroughs in tissue analysis, biomarkers, and pathology technology.
Flagship Biosciences hires Tom Turi, Ph.D. as CSO
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics. BROOMFIELD, Colo., September 27, 2022—Flagship Biosciences, Inc., a leader in
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics services BROOMFIELD, Colo., August 31, 2022—Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics
Paige and Flagship Biosciences Announce Partnership to Expand Access to Immuno-Oncology Biomarker Analysis Tools
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue types NEW YORK and BROOMFIELD, COLO. — February 17,
Flagship Biosciences Listed Among 2022 Colorado Best Small Companies to Work For
Flagship Biosciences Earns Recognition as One of the Best Small Companies to Work For in Colorado January 5, 2022 // Broomfield, CO —Today, Built In
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True Value By Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and
Flagship Biosciences Expands Tissue Image Analysis Capabilities at New Colorado Location in Support of Pharmaceutical and Clinical Clients
Broomfield, Colorado (June 1, 2021) — Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters
